INTRODUCTION
Atypical hemolytic uremic syndrome (aHUS) is one of the prototypic thrombotic microangiopathy syndromes. The salient features include thrombi, endothelial cell damage, thrombocytopenia, and hemolysis. 1 It has significant overlapping features with thrombotic thrombocytopenic purpura (TTP), although mechanistically they are distinct. 2 Very critical to the pathogenesis of aHUS is dysregulation of complement activation.
There are 2 main complement pathways, that is, the classic and alternate pathways. Activation of either pathway initiates the formation of membrane attack complex (MAC). 3 The MAC complex is composed of C5b, C6, C7, C8, and C9 and hence also falls under the designation of C5b-9; it can generate pores on target cells and activate intracellular processes including those associated with a prothrombotic state and, if numerous enough, cell death. 4 However, the MAC complex is inhibited by various regulatory proteins, of which the most important is CD59. The other complement inhibitors include CD46, Factor H, a cofactor of factor 1, and a decay accelerator of C3-convertase. 5 Factor H is the main inhibitor of complement in the fluid phase of nonactivating surfaces. There are also 5 Factor H (FH)-related proteins that may regulate complement activation, which are located on chromosome 1q32. 6 Genetic mutations in the aforesaid FH-related proteins can predispose to disease including aHUS. The FH mutations can have variable clinical effects. The main polyanion binding surface recognition is located in the C-terminus area in FH. This area also has a C3d binding site. R1210C mutation of FH, present as a rare polymorphism in geographically separated human populations, is also an associated aHUS mutation. 7 The long pentraxin (PTX3) is an acute phase protein, which plays an important role in the innate immunity by binding to complement protein C1q, regulating apoptotic cell clearance and limiting tissue damage in inflammatory conditions. Two binding sites for PTX3 are located on FH. The primary binding site is located on FH domains [19] [20] , which interact with the N-terminal domain of PTX3, whereas a secondary binding site on domain 7 binds the glycosylated PTX3 pentraxin domain. Surfacebound PTX3 enhances FH recruitment and iC3b deposition. 8 Mutations in FH impair the interaction of FH with PTX3, impairing important complement regulatory mechanisms. Complete Factor H deficiency causes dense deposit disease, which is attributed to massive amounts of C3b that accumulate in the kidney. 9 There are certain mutations that have been implicated in aHUS, including FH, Factor 1, CD46, C3, Factor B, and thrombomodulin.
Although the skin is rarely involved in aHUS, it is the most easily accessible organ for biopsy. We postulated that a biopsy of normal skin could potentially reveal evidence of systemic dysregulated complement activation characterized by microvascular deposition of MAC/C5b-9 as the end point. We describe biopsy findings of normal skin procured from a cohort of 9 patients with diagnostic clinical features of aHUS and 13 patients without diagnostic features of aHUS but in whom sufficient clinical abnormalities prompted a biopsy to rule out aHUS.
MATERIALS AND METHODS
Biopsies of skin were procured from 9 patients with HUS. Eight of these patients had diagnostic features of aHUS, whereas 1 patient had Escherichia coli-triggered HUS. In addition, 13 biopsies were obtained from patients who did not fulfill diagnostic clinical criteria of aHUS. In most cases, biopsies were available for both routine light microscopy and immunofluorescent (IF) studies. The paraffin-embedded samples were examined by routine hematoxylin and eosin, and an assessment for the deposition of MAC/C5b-9, C3d, and C4d was examined by a diaminobenzidine technique. MAC/C5b-9, C3d, and C4d within the epidermal basement membrane zone (BMZ), the BMZ of the eccrine coil, the elastic fibers in the dermis, and the elastic lamina of vessels were considered nonspecific staining patterns. The IF and immunohistochemical assay for evaluating deposition of MAC/C5b-9, C3d, and C4d conducted on fresh tissue has been previously described. 10 Our immunohistochemical protocol for the assessment of C3d, C4d, and MAC/C5b-9 has been previously described and used (Vision Bio Systems) for C3d and C4d and (Leica Microsystems) for MAC/C5b-9. 11, 12 
RESULTS

Cases of Diagnostic aHUS
Five women and 4 men aged 25-71 years (mean, 46 years) comprised the 9 patients of the study group. One patient had classic E. coli-triggered HUS. Clinical features common to all 9 patients included renal insufficiency, abnormalities in liver function tests, hemolysis, and thrombocytopenia. Among underlying medical conditions were myelofibrosis, colonic adenocarcinoma, membranous glomerulonephritis, idiopathic pancreatitis, sepsis in the setting of chorioamnionitis, and sepsis induced by retention of products of conception.
In 2 patients from the cohort, both women, cutaneous lesions were observed on examination. One patient, a 24-yearold woman, presented with sepsis and disseminated intravascular coagulation (DIC) secondary to chorioamnionitis in the 16th week of pregnancy. She was found to have retiform purpura on the left fourth toe. The other patient had cutaneous ulcers of the second toe.
Subsequent to the biopsy, clinical follow-up was available for 7 of the patients. Five of these patients received eculizumab and exhibited a dramatic response with improvement of renal function along with normalization of anemia and thrombocytopenia. In regard to the other 2 patients, 1 received conservative management only and the other patient responded well to plasma exchange.
Of the 5 patients who received eculizumab, one patient, a 59-year-old man, had been diagnosed with membranous glomerulonephritis and developed renal failure at the age of 33 years, followed by recurrent renal graft failure attributed to calcineurin inhibitor-related renal thrombotic microangiopathy. He had a successful salvage of the second graft by discontinuation of the calcineurin inhibitor and initiation of eculizumab. A diagnosis was made of calcineurin inhibitor aHUS. One patient, a 71-year-old woman, exhibited a clinical picture of pancreatitis without an apparent etiology coincident with microangiopathic hemolytic anemia, thrombocytopenia, hypocomplementemia (decreased serum C3 concentration), and a normal ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif member 13) activity. Atypical HUS seemed to be the most plausible diagnosis. A biopsy of the normal skin confirmed the diagnosis of aHUS, and the patient exhibited significant laboratory and clinical improvement after 4-5 weeks of treatment with eculizumab. Another patient, a 52-year-old woman, with myelofibrosis and severe refractory hemolytic anemia and thrombocytopenia responded very well to eculizumab after few weeks of therapy. One patient, a 34-year-old woman, developed hemolysis and renal failure in the setting of sepsis induced by retention of products of conception. The patient was resistant to plasmapheresis but had a striking response to eculizumab. The last patient, a 24-year-old woman, with E. coli sepsis and disseminated intravascular coagulation in the setting of chorioamnionitis and ulcerated toe responded very well to treatment.
Light Microscopic Findings
Five of the 9 patient biopsies were obtained from normal skin of the forearm and/or deltoid. In 1 patient, the biopsy was procured from both the toe ulcer and the normal arm skin. In 1 patient, only a biopsy of the toe ulcer was obtained, and in another patient, a normal skin biopsy from the lower extremity was obtained. In 1 patient, the biopsy site was not specified.
In most biopsies, subtle abnormalities pointing toward an underlying procoagulant state were identified. There was focal endothelial cell detachment with loose small intraluminal thrombi composed of platelets admixed with fibrin ( Fig. 1 ). Vasculitic changes were never seen. In biopsies from cutaneous ulcerative lesions, a marked occlusive pauciinflammatory thrombogenic vasculopathy with ischemic alterations of the skin was observed ( Fig. 2 ).
Evaluation of Complement Deposition on Formalin-Fixed Biopsy Material
There was extensive intense +3/3granular deposition for C3d, C4d (Fig. 3) , and C5b-9 ( Fig. 4 ) involving many vessels throughout the dermis. In certain cases, the vascular deposits were most conspicuous in the deeper dermis in apposition to the eccrine coil and in the subcutaneous fat. The staining involved the endothelium and abluminal aspect of the vessel with variable involvement of the remainder of the vessel wall and surrounding perivascular tissue. As previously mentioned, deposition for any of these aforesaid components of complement activation along the dermal-epidermal junction (DEJ) and within elastic tissue including the elastic of vessels was not considered pathogenetically significant. In 1 case, significant deposits of complement were not seen in the random normal skin biopsy of the arm. This patient had HUS rather than aHUS. In another patient, the biopsy was performed subsequent to the initiation of eculizumab therapy. In this particular biopsy, the There is prominent localization of C4d to involve the abluminal aspect of the capillary. Similar deposits were noted in venules and small arteries. The deposition pattern was conspicuous superficially but was also noted throughout the dermis. extent of MAC/C5b-9 was mild-to-moderate and significantly less than those cases in which the eculizumab was started after the biopsy.
Immunofluorescent Studies Conducted on Frozen Tissue
In all cases except 2, there was extensive granular deposition of MAC/C5b-9 in vessels throughout the dermis (Figs. 5A,B ). The vascular deposits could be accentuated in the deeper dermis and involve the subcutaneous fat. Deposition along the DEJ, highlighting elastic fibers including the elastic lamina of blood vessels and within the BMZ of the eccrine coil were not considered significant. There was pronounced fibrinogen deposition within vessels in all biopsies ( Fig. 6 ).
Patients Without Diagnostic Clinical Features of aHUS
Ten women and 3 men ranging in age from 18 to 64 years (mean, 40 years) comprised the cohort of patients without clinical aHUS features. Although there was one or more isolated feature that could be seen in aHUS, however, in none of these cases were the clinical presentation and laboratory findings diagnostic of aHUS; the patients were believed to have other conditions apart from aHUS. The various illnesses in these 13 patients are described briefly in Table 1 .
None of these patients received eculizumab except 3 patients with diagnostic features of TTP. As these patients are unusual and raise consideration in regard to a TTP/aHUS overlap, they will be considered in greater detail. One patient was a 27-year-old-man who had classic TTP with no detectable ADAMTS13 on the basis of autoantibodies directed at ADAMTS13. He had a skin biopsy of the left thigh to rule out aHUS, which revealed extensive deposits of MAC/C5b-9 demonstrated both by immunohistochemistry and immunofluorescence. As the patient was refractory to other therapies for TTP including intravenous gamma globulin and plasmapheresis, he received eculizumab with a rapid and striking improvement. This case has been previously reported. 13 The patient was subsequently discovered to have a complement regulatory protein mutation implicated in aHUS (Fig. 7) . The second patient was an 18-year-old woman admitted with severe abdominal pain, anemia, and thrombocytopenia. Her course was complicated by slurred speech, dyspnea, and chest pain. She was found to have hemolysis and received IVIg and steroids with no success. ADAMS13 activity was ,10, and she began to have episodes of abnormal mental status. In the meanwhile, a skin biopsy was performed, which showed significant complement deposits, and eculizumab was initiated along with plasmapheresis. However, she had no response to therapy, and after 3 days, she developed seizures followed by cardiac arrest and death. An autopsy was performed and revealed diffuse microthrombi in the heart, lungs, liver, and kidneys, as well as gross hemorrhage through the entire GI tract, consistent with a diagnosis of TTP. The third patient, a 22-year-old woman, presented with right-sided weakness and was found to have anemia and thrombocytopenia while she was 2 months pregnant and subsequently was diagnosed with TTP and received plasma exchange and IVIg without response. She developed a gradually rising creatinine and was started on dialysis. A skin biopsy was performed, which did not show evidence of complement deposition. However, she was given eculizumab with no response. Over the next few days, she became lethargic and developed respiratory deterioration and cardiac arrest. An autopsy showed multifocal cardiac myocyte necrosis and several organizing thrombi within the cardiac arterioles, renal glomerular arterioles, and brain capillaries. 
Light Microscopy
In 9 patients, the biopsies were performed from the forearm or deltoid. In 2 patients, the biopsy was performed from normal abdominal skin, and in another patient, the biopsy was performed from normal skin of the lower extremity. In 1 patient, the biopsy site was not specified.
Significant abnormalities were not seen excluding 2 patients with TTP in whom there were focal chronic microvascular changes correlating with significant vascular deposits of MAC/C5b-9.
Evaluation of Complement on Formalin-Fixed Biopsy Material
Significant deposition for C3d, C4d, and MAC/C5b-9 was not observed in any of the cases, except 2 cases of TTP including one where the patient had a complement regulatory gene mutation defining what is in essence of an overlapping TTP and aHUS picture clinically.
Direct Immunofluorescent Studies
In all cases excluding the 2 patients with TTP, vascular deposition for MAC/C5b-9 was not observed. Deposition along the DEJ, on elastic fibers including the elastic lamina of blood vessels and within the BMZ of the eccrine coil, was not considered significant and was observed in most biopsies.
DISCUSSION
The skin biopsy has the potential to play a very important role in the diagnosis of aHUS. Paradoxically, clinical features indicative of cutaneous involvement in the setting of aHUS is rarely described. Although the exact defect in complement regulation cannot be elucidated in every case, the common mechanism of vascular injury is MAC/C5b-9 deposition and has important therapeutic implications with respect to the implementation of eculizumab. Eculizumab is a monoclonal antibody that binds C5, prohibiting its division into C5a and C5b; C5a acts as an anaphylatoxin, and C5b initiates the formation of the MAC/C5b-9 with the coordination of C6-C9. Prevention of the formation of C5a and MAC/C5b-9 inhibits complement-mediated thrombotic microangiopathy. [14] [15] [16] [17] [18] [19] [20] Eculizumab first received approval for the treatment of patients with paroxysmal nocturnal hemoglobinuria in 2007, 14, 19, 21 followed by multiple retrospective and prospective trials enrolling adult, adolescent, or pediatric patients with aHUS. These trials led to an accelerated approval for the use of eculizumab for the treatment of pediatric and adult patients with aHUS in 2011. Eculizumab resulted in elimination of the requirement for dialysis or plasma therapy, sustained improvement in the estimated glomerular filtration rate, and hematologic parameters that correlate with aHUS disease activity. [14] [15] [16] [17] [18] [22] [23] [24] Two patients in our series had skin lesions in the context of symptomatic aHUS, emphasizing that the skin is a targeted organ site despite the infrequency with which cutaneous involvement has been reported. There are only 2 prior reports of cutaneous lesions in the setting of aHUS. One child presented shortly after birth with thrombocytopenia, hemolytic anemia, and acute renal failure. His course was complicated by multiple intestinal perforations and cutaneous ulcers. The patient responded very quickly to eculizumab. Subsequent investigations revealed antibodies to factor H. 15 An additional study described a 4-year-old Indian girl who developed gangrene of the fingertips 2 days after initial presentation of aHUS. Factor H autoantibodies were identified. Renal function continued to decline despite daily plasma exchanges, and she was started on peritoneal dialysis 5 days after admission. The patient died. Another patient developed end-stage renal disease due to aHUS in the fourth month after birth. A de novo activating C3 mutation was found. At the age of 9 months, she developed ischemic changes in fingers of both hands and several toes, which did not improve with plasma exchange therapy. The patient had an almost complete response to the eculizumab. All nonnecrotic digits rapidly regained perfusion. The 3 already gangrenous fingers healed with loss of the distal phalanges. 25 In this study, both patients with cutaneous lesions were women, whereby there was a predilection for acral involvement manifesting as ulcers and background livedo. Both of these patients were treated with eculizumab with an excellent clinical response.
In this study, the biopsies in patients with aHUS were largely performed on normal appearing skin; in this regard, the light microscopic abnormalities were very subtle. In the vast majority of cases, only mild microvascular changes were identified. In particular, we noted some degree of BMZ reduplication and small loose intraluminal platelet thrombi. Despite the relative paucity of changes observed by routine light microscopy, all patients except 2 showed prominent MAC/C5b-9 with variable deposition of C3d and C4d involving the endothelium and the vessel wall. The principle caliber of vessels affected was capillaries, venules, and small arterioles. A virtually identical pattern was seen by direct IF testing in terms of intensity of MAC/C5b-9 and the relative distribution of C5b-9. Any staining of the elastic tissue of the dermis especially within the elastic lamina of blood vessels and epithelial BMZ was interpreted as being nonspecific. A significant staining pattern had to be endothelial-based and/or at least abluminal, affecting smaller caliber vessels, namely capillaries, venules, and small arterioles. In 1 patient with clinical features of aHUS, the biopsy was performed while the eculizumab therapy was initiated. In this particular biopsy, the extent of MAC/C5b-9 was mild-to-moderate, which is most likely related to the fact that the patient was receiving treatment. A comparable degree of microvascular changes and complement deposition was not apparent in most cases that were not clinically diagnostic of aHUS. A number of biopsies were performed on patients who had symptoms encountered in aHUS but had other reasons such as systemic lupus erythematous, HELLP, and TTP as the etiologic basis of the multiorgan thrombotic diathesis and/or hemolysis and/or did not have enough symptoms and abnormal laboratory findings to render a diagnosis of aHUS. Overall, there was either no or minimal and focal complement deposition in qualitative and quantitative contrast to those patients with aHUS who exhibited prominent deposition. Interestingly, in 1 patient with HUS triggered by E. coli infection, complement deposition was not identified on a normal skin biopsy.
In 2 cases of TTP, there were prominent deposits of C5b-9 in smaller caliber vessels, with 1 patient demonstrating a very positive response to eculizumab. This particular patient was very interesting based on fulfilling diagnostic features of TTP including an absent ADAMSTS13 along with a genetic mutation implicated in aHUS. Indeed, his first cousin had developed aHUS as a child. Whether or not a similar overlapping aHUS and TTP picture was operational in the other TTP patient exhibiting extensive vascular MAC/C5b-9 is unclear. It should be emphasized that there is likely a subset of patients with TTP who may have genetic mutations which define an aHUS clinical phenotype (Fig. 7) . Conversely, authors have shown genetic variations in the ADAMTS13 gene to partially explain the reduced activity known to occur in some patients with aHUS. In their study, they found reduced complement and ADAMTS13 activity in more than 60% and 50% of patients, respectively. 26 Severe ADAMTS13 deficiency leads to generation of massive platelet thrombi, which might contribute to complement activation. 27 Increased levels of C3a and MAC/C5b-9 were observed in TTP during acute episodes, as compared with healthy controls. Decreased complement C3 levels indicative of complement consumption occurred in 15% of patients with acute TTP. Significant decrease of complement activation products C3a and C5b-9 was observed during plasma exchange. The sustained presence of anti-ADAMTS13 inhibitory antibodies in complete remission was associated with increased complement activation. 26 In the majority of cases in this study, the biopsies were of normal skin from the forearm or deltoid. In 1 patient, a biopsy was only performed from the toe ulcer, and in another patient, biopsies were taken from both the normal deltoid skin and a toe ulcer. In 2 patients, biopsies were performed only on the lower extremity. Two patients had a biopsy of normal abdominal skin. We recommend the deltoid area to reduce the incidence of false positivity, which may occur when using sun-exposed skin or lower extremity skin. Ultraviolet light exposure can lead to complement activation, especially if the patient is taking a photosensitizing drug or is applying a contactant with photosensitizing properties. In the same vein, it is well established that the lower extremity vessels are preferential sites for immune complex entrapment, reflective of hydrostatic pressure. Hence, there may be a low level of insidious complement activation occurring within the lower extremity microvasculature leading to a higher incidence of false-positive results.
In summation, the skin biopsy is of value in establishing a diagnosis of aHUS even in the absence of clinically discernible skin lesions. From a light microscopic perspective, subtle alterations include chronic microvascular alterations with BMZ reduplication along with evidence of a procoagulant state. The microvascular deposition of MAC/C5b-9 through the dermis and subcutaneous fat as identified by both immunohistochemistry and by direct immunofluorescence using nonlesional skin appears to be a reproducible pattern and is a reliable marker of aHUS and likely a subset of patients with TTP. It is important to appreciate patterns of MAC/C5b-9 deposition that are not pathologically relevant to avoid overdiagnosis of aHUS and eculizumab responsive variants of TTP.
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